Pharmafile Logo

Bristol-Myers Squibb Co

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Bristol-Myers Squibb Co in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Bristol-Myers Squibb Co.

Recent articles on PMLiVE featuring Bristol-Myers Squibb Co

- PMLiVE
Bristol Myers Squibb’s injectable Opdivo formulation granted FDA approval

Opdivo Qvantig can be administered in three to five minutes compared to 30 minutes for the drug’s IV form

- PMLiVE
Bristol Myers Squibb’s Augtyro granted expanded FDA approval for solid tumours

The drug was approved by the US regulator last year to treat ROS1-positive NSCLC

- PMLiVE
BMS shares positive phase 3 results for Opdivo/Yervoy combination in liver cancer

Hepatocellular carcinoma accounts for 90% of all liver cancer cases and is often diagnosed at an advanced stage

- PMLiVE
Bristol Myers Squibb’s Breyanzi receives FDA approval for mantle cell lymphoma

The rare form of non-Hodgkin lymphoma accounts for around 3% of all NHL cases

- PMLiVE
Bristol Myers Squibb’s Opdivo approved by EC for adults with urothelial carcinoma

UC accounts for approximately 90% of all bladder cancers, the ninth most common cancer globally

- PMLiVE
Bristol Myers Squibb shares positive phase 3 results for Krazati in non-small cell lung cancer

KRAS G12C occurs in approximately 14% of NSCLC, the most common form of lung cancer

Tooth and nail

With Merck and BMS first out of the gates, here comes the assault on the Inflation Reduction Act

- PMLiVE
Astellas and PeptiDream announce protein degrader research collaboration

Protein degrader drugs have been proposed as a way to address ‘undruggable’ targets

- PMLiVE
Ipsen reports positive phase 3 data for Onivyde in pancreatic cancer

The investigational treatment regimen met its primary endpoint of overall survival

Bristol Myers Squibb logo
BMS’ CAR T therapy Breyanzi shows benefit in B-cell lymphoma study

Breyanzi demonstrated a statistically significant improvement in event-free survival compared to standard of care

- PMLiVE
BMS and bluebird bio gain FDA approval for multiple myeloma therapy

Abecma is a CAR T cell therapy approved for pre-treated myeloma patients

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links